Retraction Note: Psychopharmacology (2020) 238:581–588
10.1007/s00213-020-05710-w
The Editors have retracted this article after they were informed of protocol violations amounting to unethical conduct at the MP4 study site by researchers associated with this project. The authors have subsequently confirmed that they were aware of these violations at the time of submission of this article, but did not disclose this information to the journal or remove data generated by this site from their analysis. Additionally, the authors also did not fully declare a potential competing interest. Two of the authors are affiliated with the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC), a subsidiary that is wholly owned by the Multidisciplinary Association for Psychedelic Studies (MAPS). As is stated in the Funding declaration, MAPS fully funded and provided the MDMA that was used in this trial, and MAPS PBC organised the trial.
Allison A. Feduccia agrees with this retraction but disagrees with the wording of the retraction notice. Lisa Jerome, Michael C. Mithoefer, and Julie Holland disagree with this retraction.
Footnotes
The online version of the original article can be found at 10.1007/s00213-020-05710-w.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.